GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » EV-to-FCF

Pharma Mar (XMAD:PHM) EV-to-FCF : -13.33 (As of May. 12, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharma Mar's Enterprise Value is €463.6 Mil. Pharma Mar's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-34.8 Mil. Therefore, Pharma Mar's EV-to-FCF for today is -13.33.

The historical rank and industry rank for Pharma Mar's EV-to-FCF or its related term are showing as below:

XMAD:PHM' s EV-to-FCF Range Over the Past 10 Years
Min: -986.01   Med: 5.02   Max: 420.94
Current: -13.33

During the past 13 years, the highest EV-to-FCF of Pharma Mar was 420.94. The lowest was -986.01. And the median was 5.02.

XMAD:PHM's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs XMAD:PHM: -13.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Pharma Mar's stock price is €33.30. Pharma Mar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.108. Therefore, Pharma Mar's PE Ratio for today is 308.33.


Pharma Mar EV-to-FCF Historical Data

The historical data trend for Pharma Mar's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar EV-to-FCF Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.30 4.16 48.92 34.77 -20.60

Pharma Mar Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 420.93 -29.03 -15.04 -20.60 -11.03

Competitive Comparison of Pharma Mar's EV-to-FCF

For the Biotechnology subindustry, Pharma Mar's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharma Mar's EV-to-FCF falls into.



Pharma Mar EV-to-FCF Calculation

Pharma Mar's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=463.553/-34.78
=-13.33

Pharma Mar's current Enterprise Value is €463.6 Mil.
Pharma Mar's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Mar  (XMAD:PHM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharma Mar's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=33.30/0.108
=308.33

Pharma Mar's share price for today is €33.30.
Pharma Mar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.108.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharma Mar EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharma Mar's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar (XMAD:PHM) Business Description

Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar (XMAD:PHM) Headlines

From GuruFocus

Q1 2022 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2021 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2019 PulteGroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

PulteGroup Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024